Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| MindMaze Therapeutics Holding SA | RLF-OD032 | Phenylketonuria (PKU) | NDA Filing | Data Released | Oral | Genetic Disorder |
| MindMaze Therapeutics Holding SA | Remdesivir and ZYESAMI (Aviptadil) - (ACTIV-3b NIH trial) | COVID-19 | Phase 3 | Trial Discontinued | Intravenous | COVID-19 |
| MindMaze Therapeutics Holding SA | RLF-100 | Pulmonary sarcoidosis | Phase 2b | Trial Planned | intravenous | Respiratory |
| MindMaze Therapeutics Holding SA | ACER-001 | Maple Syrup Urine Disease (MSUD) | Phase 2a | Trial Planned | Oral | Genetic Disorder |
| MindMaze Therapeutics Holding SA | ACER-001 | Maple Syrup Urine Disease (MSUD) | Phase 2a | Trial Planned | Oral | Genetic Disorder |
| Mineralys Therapeutics Inc. | Lorundrostat - (Launch-HTN) | Uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). | NDA Filing | Ongoing | Oral | Cardiology |
| Mineralys Therapeutics Inc. | Lorundrostat - (EXPLORE-OSA) | Obstructive Sleep Apnea and Hypertension | Phase 2 | Enrollment Conclusion | Oral | Respiratory |
| Mineralys Therapeutics Inc. | Lorundrostat - (Explore-CKD) | Moderate-to-severe obstructive sleep apnea (OSA) and hypertension | Phase 2 | Data Released | Oral | Respiratory |
